查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
前列腺癌治療藥物市場-全球行業規模、份額、趨勢、機會、預測：按治療（激素療法、化學療法、免疫療法、趨勢療法、其他）、最終用戶、競爭對手（2018-）2028）
市場調查報告書
商品編碼
1244148

前列腺癌治療藥物市場-全球行業規模、份額、趨勢、機會、預測：按治療（激素療法、化學療法、免疫療法、趨勢療法、其他）、最終用戶、競爭對手（2018-）2028）

Prostate Cancer Therapeutics Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Others), By End User
出版日期: | 出版商: TechSci Research | 英文 111 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球前列腺癌藥物市場預計到 2028 年將經歷令人矚目的增長。

男性前列腺的異常細胞生長和肥大被稱為前列腺癌。 總體而言，前列腺癌是男性第 10 大死因和第 6 大死因。 前列腺癌的治療包括手術、激素療法、放射療法、化學療法和生物療法。 前列腺癌、小細胞癌和良性前列腺增生症等診斷和治療用於前列腺癌的治療和管理。

不斷增長的老年人口

前列腺癌是美國男性最常見的癌症，不包括非黑色素瘤皮膚癌。 它也是包括西班牙裔在內的所有種族男性癌症死亡的主要原因之一。 每 10 名 65 歲以上的男性中就有 6 名患有此病，而在 40 歲以下的男性中則很少見。 前列腺癌是美國男性中僅次於肺癌的第二大常見癌症。 美國的前列腺癌新病例預計將從 2009 年的 192,280 例增加到 2022 年的約 268,490 例。 此外，據估計，到 2022 年美國將有大約 34,500 名男性死於前列腺癌，這將增加美國對前列腺癌藥物的需求。

推出新的治療藥物

由於診斷技術的進步，前列腺癌的診斷已經發生了變化。 監測 PSA 水平有助於檢測前列腺癌。 幾種新的細胞毒性藥物、激素療法和其他抗前列腺特異性膜抗原療法的 II 期和 III 期試驗正在進行中。 梅奧醫學教育和研究基金會 (MFMER) 表示，激素療法和抗細胞毒性 T 淋巴細胞相關抗原 (CTLA) 療法的結合可以誘導針對前列腺腫瘤的靶向免疫反應。 因此，治療創新有望推動全球前列腺癌治療市場的增長。 此外，主要市場參與者的產品發布和藥物創新預計將推動全球前列腺癌治療市場的增長。

激素治療的副作用

前列腺癌是一種慢性病，治療週期長。 激素治療的副作用包括勃起功能障礙、潮熱、骨密度下降、骨折、肌肉質量和力量下降、血脂變化、胰島素抵抗、體重增加、情緒波動、疲勞、乳房組織生長（女性化）。 ）， ETC。 因此，長期接受激素治療會影響個人的日常生活並增加出現健康問題的風險。

此外，副作用因人而異，用於治療癌症的劑量也是如此。 因此，癌症治療的副作用預計會阻礙市場增長。

市場細分

前列腺癌治療藥物的全球市場根據治療方法和最終用戶進行細分。 基於療法，市場分為激素療法、化學療法、免疫療法和靶向療法。 激素療法進一步分為黃體生成素釋放激素 (LHRH) 拮抗劑、激素釋放激素 (LHRH) 激動劑和抗雄激素。 化療領域分為taxotere和jevtana。 免疫療法包括 Provenge，靶向療法包括 Xofigo 等。 最終用戶部分進一步細分為醫院、專科診所、門診手術中心等。

近期發展

  • 2022 年 3 月，BioPharma 宣布獲得用於成年晚期前列腺癌患者的 42 毫克注射乳劑“CAMC□□EVI（亮丙瑞林）”的許可。 該業務還提供對 AccordConnects 的訪問，AccordConnects 是用於 Camcevi 庫存管理的移動應用程序。

營銷人員

Johnson &Johnson;Services Inc;Astellas Pharma Inc;Eli Lilly and Company;Sanofi;Ipsen Pharma;Bayer AG;AstraZeneca;Valeant Pharmaceuticals International, Inc;Merck &Co., Inc; 它是製藥市場的主要參與者.

報告範圍

本報告將全球前列腺癌治療市場分為以下幾類，以及下面詳述的行業趨勢：

前列腺癌藥物市場，按治療：

  • 激素療法
    • 促黃體激素釋放激素 (LHRH) 拮抗劑
    • 促黃體激素釋放激素 (LHRH) 激動劑
    • 抗雄激素
  • 化療
    • 泰索帝
    • 傑夫塔納
  • 免疫療法
    • 普羅旺斯
  • 靶向治療
    • X 福伊戈
  • 其他

前列腺癌藥物市場，按最終用戶分類：

  • 醫院
  • 專科診所
  • 門診手術中心
  • 其他

按地區劃分的前列腺癌藥物市場：

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 法國
    • 德國
    • 英國
    • 意大利
    • 西班牙
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳大利亞
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
  • 中東和非洲
    • 阿聯酋
    • 南阿拉伯
    • 沙特阿拉伯
    • 土耳其人
    • 埃及

競爭格局

公司概況：對全球前列腺癌治療市場主要參與者的深入分析。

可自定義：

根據市場數據，TechSci Research 根據公司的具體需求提供定制服務。 該報告可以定制為：

公司信息

  • 對其他市場公司（最多 5 家公司）進行深入分析和概況分析。

內容

第一章服務概述

  • 市場定義
  • 市場範圍
    • 目標市場
    • 研究目標年份
    • 主要市場細分

第二章研究方法論

  • 調查目的
  • 基線調查方法
  • 主要行業合作夥伴
  • 主要協會和次要信息
  • 調查方法
  • 數據三角測量和驗證
  • 假設和限制

第 3 章執行摘要

  • 市場概覽
  • 主要市場細分概述
  • 主要市場參與者概覽
  • 主要地區/國家概覽
  • 市場驅動因素、挑戰和趨勢概述

第 4 章 VOC（客戶之聲）

第五章全球前列腺癌藥物市場展望

  • 市場規模和預測
    • 按價值觀
  • 市場份額和預測
    • 按治療方法（激素療法、化學療法、免疫療法、靶向療法等）
    • 最終用戶（醫院、腫瘤診所、門診手術中心等）
    • 按地區
    • 按公司分類（2022 年）
  • 市場地圖
    • 通過治療
    • 最終用戶

第六章北美前列腺癌藥物市場前景

  • 市場規模和預測
    • 按價值觀
  • 市場份額和預測
    • 按治療方法（激素療法、化學療法、免疫療法、靶向療法等）
    • 最終用戶（醫院、腫瘤診所、門診手術中心等）
    • 按國家
  • 北美：國家/地區分析
    • 美國前列腺癌藥物市場前景
      • 市場規模和預測
        • 按價值觀
      • 市場份額和預測
        • 通過治療
        • 最終用戶
    • 加拿大前列腺癌藥物市場前景
      • 市場規模和預測
        • 按價值觀
      • 市場份額和預測
        • 通過治療
        • 最終用戶
    • 墨西哥前列腺癌藥物市場前景
      • 市場規模和預測
        • 按價值觀
      • 市場份額和預測
        • 通過治療
        • 最終用戶

第七章歐洲前列腺癌藥物市場前景

  • 市場規模和預測
    • 按價值觀
  • 市場份額和預測
    • 按治療方法（激素療法、化學療法、免疫療法、靶向療法等）
    • 最終用戶（醫院、腫瘤診所、門診手術中心等）
    • 按國家
  • 歐洲：國家分析
    • 法國前列腺癌藥物市場前景
      • 市場規模和預測
        • 按價值觀
      • 市場份額和預測
        • 通過治療
        • 最終用戶
    • 德國前列腺癌藥物市場前景
      • 市場規模和預測
        • 按價值觀
      • 市場份額和預測
        • 通過治療
        • 最終用戶
    • 英國前列腺癌藥物市場的前景
      • 市場規模和預測
        • 按價值觀
      • 市場份額和預測
        • 通過治療
        • 最終用戶
    • 意大利前列腺癌藥物市場前景
      • 市場規模和預測
        • 按價值觀
      • 市場份額和預測
        • 通過治療
        • 最終用戶
    • 西班牙前列腺癌藥物市場前景
      • 市場規模和預測
        • 按價值觀
      • 市場份額和預測
        • 通過治療
        • 最終用戶

第8章亞太地區前列腺癌藥物市場前景

  • 市場規模和預測
    • 按價值觀
  • 市場份額和預測
    • 按治療方法（激素療法、化學療法、免疫療法、靶向療法等）
    • 最終用戶（醫院、腫瘤診所、門診手術中心等）
    • 按國家
  • 亞太地區：國家/地區分析
    • 中國前列腺癌藥物市場展望
      • 市場規模和預測
        • 按價值觀
      • 市場份額和預測
        • 通過治療
        • 最終用戶
    • 日本前列腺癌藥物市場前景
      • 市場規模和預測
        • 按價值觀
      • 市場份額和預測
        • 通過治療
        • 最終用戶
    • 印度前列腺癌藥物市場前景
      • 市場規模和預測
        • 按價值觀
      • 市場份額和預測
        • 通過治療
        • 最終用戶
    • 韓國前列腺癌藥物市場的前景
      • 市場規模和預測
        • 按價值觀
      • 市場份額和預測
        • 通過治療
        • 最終用戶
    • 澳大利亞前列腺癌藥物市場前景
      • 市場規模和預測
        • 按價值觀
      • 市場份額和預測
        • 通過治療
        • 最終用戶

第9章南美前列腺癌藥物市場前景

  • 市場規模和預測
    • 按價值觀
  • 市場份額和預測
    • 按治療方法（激素療法、化學療法、免疫療法、靶向療法等）
    • 最終用戶（醫院、腫瘤診所、門診手術中心等）
    • 按國家
  • 南美洲：：國家分析
    • 巴西前列腺癌藥物市場前景
      • 市場規模和預測
        • 按價值觀
      • 市場份額和預測
        • 通過治療
        • 最終用戶
    • 阿根廷前列腺癌藥物市場前景
      • 市場規模和預測
        • 按價值觀
      • 市場份額和預測
        • 通過治療
        • 最終用戶
    • 哥倫比亞前列腺癌藥物市場前景
      • 市場規模和預測
        • 按價值觀
      • 市場份額和預測
        • 通過治療
        • 最終用戶

第 10 章中東和非洲前列腺癌藥物市場展望

  • 市場規模和預測
    • 按價值觀
  • 市場份額和預測
    • 按治療方法（激素療法、化學療法、免疫療法、靶向療法等）
    • 最終用戶（醫院、腫瘤診所、門診手術中心等）
    • 按國家
  • MEA：國家分析
    • 阿聯酋前列腺癌藥物市場前景
      • 市場規模和預測
        • 按價值觀
      • 市場份額和預測
        • 通過治療
        • 最終用戶
    • 沙特阿拉伯的前列腺癌藥物市場前景
      • 市場規模和預測
        • 按價值觀
      • 市場份額和預測
        • 通過治療
        • 最終用戶
    • 沙特阿拉伯的前列腺癌藥物市場前景
      • 市場規模和預測
        • 按價值觀
      • 市場份額和預測
        • 通過治療
        • 最終用戶
    • 土耳其前列腺癌藥物市場前景
      • 市場規模和預測
        • 按價值觀
      • 市場份額和預測
        • 通過治療
        • 最終用戶
    • 埃及前列腺癌藥物市場前景
      • 市場規模和預測
        • 按價值觀
      • 市場份額和預測
        • 通過治療
        • 最終用戶

第 11 章市場動態

  • 司機
    • 前列腺癌的患病率增加
    • 採用新的篩查和診斷技術
    • 研發快速增長
  • 做
    • 昂貴的癌症治療費用
    • 關於激素療法的副作用

第12章市場趨勢與發展

  • 產品發布
  • M&A（併購）
  • 技術進步

第13章臨床試驗分析

第 14 章全球前列腺癌藥物市場：SWOT 分析

第15章競爭格局

  • Business Overview
  • Product Offerings
  • Recent Developments
  • Financials（In Case of Listed Companies）
  • Key Personnel
  • SWOT Analysis
    • Johnson & Johnson Services, Inc.
    • Astellas Pharma Inc.
    • Eli Lilly and Company
    • Sanofi S.A.
    • Ipsen Pharma
    • Bayer AG
    • AstraZeneca Plc
    • Valeant Pharmaceuticals International, Inc.
    • Merck & Co., Inc.
    • Pfizer Inc.

第16章 戰略建議

簡介目錄
Product Code: 14698

Global prostate cancer therapeutics market is anticipated to grow at an impressive rate through 2028. The multiplication and abnormal enlargement of the prostate gland's aberrant cells in men are known as prostate cancer. Overall, the tenth leading cause of mortality and the sixth major cause of death in men is prostate cancer. Treatments for prostate cancer include surgery, hormone therapy, radiation, chemotherapy, and biological therapy. Prostatic adenocarcinoma, small cell carcinoma, benign prostatic hyperplasia, and other diagnoses and treatments are used to treat and manage prostate cancer.

An aging population, the sedentary lifestyle of those in industrialized nations, and the early start of urological problems are all factors that contribute to the prevalence of prostate cancer, globally. The rise in the geriatric population, upsurge in generic medicines, increasing awareness among people concerning the treatment of prostate cancer, availability of new prostate cancer treatments, and strong emerging pipeline drugs are the factors expected to accelerate the growth of the market. Furthermore, the rise in research and development activities and innovation in drugs is anticipated to boost the growth of the global prostate cancer therapeutics market.

Increasing Elderly Population

Prostate cancer is the most prevalent cancer among men in the US, aside from non-melanoma skin cancer. Additionally, it is one of the major causes of cancer death in males of all races including those of Hispanic ancestry. It is diagnosed in about 6 out of 10 men who are 65 and rare in men under 40. Prostate cancer is the second most common cancer among American males, after lung cancer. In the United States, it was predicted that about 268,490 new cases of prostate cancer were reported in 2022, up from 192,280 new cases in 2009. Moreover, it was estimated that, in 2022, around 34,500 men would die of prostate cancer in the U.S. This, in turn, increased the demand for prostate cancer therapeutics in the US.

Launch of Emerging Novel Therapies

The diagnosis of prostate cancer has transformed owing to advanced diagnostic technologies. The detection of prostate cancer has been assisted by the monitoring of PSA levels. Phase II and phase III trials are underway for several novel cytotoxic medications, hormonal treatments, and other anti-prostate-specific membrane antigen therapies. The Mayo Foundation for Medical Education and Research (MFMER) states that a targeted immune response can be induced against prostate tumors using a combination of hormonal and anti-cytotoxic T-lymphocyte-associated antigen (CTLA) treatment approaches. Hence, innovation in therapies is expected to enhance the growth of the global Prostate Cancer Therapeutics Market. Further, product launches and innovation in medicines by key market players have anticipated booming the growth of the global Prostate Cancer Therapeutics Market.

Side Effects of Hormonal Treatment

Prostate Cancer is a chronic disease with lengthy treatments. The side effects of hormonal treatment include erectile dysfunction, hot flashes, loss of bone density, bone fractures, loss of muscle mass and physical strength, changes in blood lipids, insulin resistance, weight gain, mood swings, fatigue, and the growth of breast tissue (gynecomastia). Hence, long exposure to hormonal treatment affects individuals' daily life and increases the risk of health problems.

Moreover, side effects vary from person to person and the dose used to treat cancer. Hence, the side effects of cancer treatment are projected to hamper the growth of the market.

Market Segmentation

The global Prostate Cancer Therapeutics Market is segmented based on treatment and end user. Based on treatment, the market is categorized into hormonal therapy, chemotherapy, immunotherapy, and target therapy. Hormonal therapy is further divided into Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists, Hormone-Releasing Hormone (LHRH) Agonists, and Anti-Androgen. The chemotherapy therapy segment is bifurcated into Taxotere and Jevtana. The immunotherapy segment includes Provenge and targeted therapy includes Xofigo and Others. The end-user segment is further segmented into Hospitals, Specialized Clinics, Ambulatory Surgical Centers, and Others.

Recent Developments

  • The introduction of CAMCEVI (leuprolide), a 42mg injection emulsion for the treatment of adults with advanced prostate cancer was announced by BioPharma in March 2022. The business also provides access to the AccordConnects mobile application for the administration of Camcevi inventories.

Market players

Johnson & Johnson; Services Inc.; Astellas Pharma Inc.; Eli Lilly and Company; Sanofi; Ipsen Pharma; Bayer AG; AstraZeneca; Valeant Pharmaceuticals International, Inc.; Merck & Co., Inc.; Pfizer Inc are the major players operating in the global prostate cancer therapeutics market.

Report Scope:

In this report, the global Prostate Cancer Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Prostate Cancer Therapeutics Market, By Treatment:

  • Hormonal Therapy
    • Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
    • Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
    • Anti-Androgen
  • Chemotherapy
    • Taxotere
    • Jevtana
  • Immunotherapy
    • Provenge
  • Targeted Therapy
    • Xofigo
  • Others

Prostate Cancer Therapeutics Market, By End User:

  • Hospitals
  • Specialized Clinics
  • Ambulatory Surgical centers
  • Others

Prostate Cancer Therapeutics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • UAE
    • South Arabia
    • Saudi Africa
    • Turkey
    • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Prostate Cancer Therapeutics Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Service Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Prostate Cancer Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
      • 5.2.1.1. Hormonal Therapy
        • 5.2.1.1.1. Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
        • 5.2.1.1.2. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
        • 5.2.1.1.3. Anti-Androgen
      • 5.2.1.2. Chemotherapy
        • 5.2.1.2.1. Taxotere
        • 5.2.1.2.2. Jevtana
      • 5.2.1.3. Immunotherapy
        • 5.2.1.3.1. Provenge
      • 5.2.1.4. Target Therapy
        • 5.2.1.4.1. Xofigo
      • 5.2.1.5. Others
    • 5.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2022)
  • 5.3. Market Map
    • 5.3.1. By Treatment
    • 5.3.2. By End User

6. North America Prostate Cancer Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
      • 6.2.1.1. Hormonal Therapy
        • 6.2.1.1.1. Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
        • 6.2.1.1.2. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
        • 6.2.1.1.3. Anti-Androgen
      • 6.2.1.2. Chemotherapy
        • 6.2.1.2.1. Taxotere
        • 6.2.1.2.2. Jevtana
      • 6.2.1.3. Immunotherapy
        • 6.2.1.3.1. Provenge
      • 6.2.1.4. Target Therapy
        • 6.2.1.4.1. Xofigo
      • 6.2.1.5. Others
    • 6.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Prostate Cancer Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Prostate Cancer Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Prostate Cancer Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment
        • 6.3.3.2.2. By End User

7. Europe Prostate Cancer Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
      • 7.2.1.1. Hormonal Therapy
        • 7.2.1.1.1. Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
        • 7.2.1.1.2. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
        • 7.2.1.1.3. Anti-Androgen
      • 7.2.1.2. Chemotherapy
        • 7.2.1.2.1. Taxotere
        • 7.2.1.2.2. Jevtana
      • 7.2.1.3. Immunotherapy
        • 7.2.1.3.1. Provenge
      • 7.2.1.4. Target Therapy
        • 7.2.1.4.1. Xofigo
      • 7.2.1.5. Others
    • 7.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Prostate Cancer Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment
        • 7.3.1.2.2. By End User
    • 7.3.2. Germany Prostate Cancer Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Prostate Cancer Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Prostate Cancer Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Prostate Cancer Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment
        • 7.3.5.2.2. By End User

8. Asia-Pacific Prostate Cancer Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
      • 8.2.1.1. Hormonal Therapy
        • 8.2.1.1.1. Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
        • 8.2.1.1.2. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
        • 8.2.1.1.3. Anti-Androgen
      • 8.2.1.2. Chemotherapy
        • 8.2.1.2.1. Taxotere
        • 8.2.1.2.2. Jevtana
      • 8.2.1.3. Immunotherapy
        • 8.2.1.3.1. Provenge
      • 8.2.1.4. Target Therapy
        • 8.2.1.4.1. Xofigo
      • 8.2.1.5. Others
    • 8.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Prostate Cancer Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment
        • 8.3.1.2.2. By End User
    • 8.3.2. Japan Prostate Cancer Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment
        • 8.3.2.2.2. By End User
    • 8.3.3. India Prostate Cancer Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Prostate Cancer Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Prostate Cancer Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment
        • 8.3.5.2.2. By End User

9. South America Prostate Cancer Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
      • 9.2.1.1. Hormonal Therapy
        • 9.2.1.1.1. Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
        • 9.2.1.1.2. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
        • 9.2.1.1.3. Anti-Androgen
      • 9.2.1.2. Chemotherapy
        • 9.2.1.2.1. Taxotere
        • 9.2.1.2.2. Jevtana
      • 9.2.1.3. Immunotherapy
        • 9.2.1.3.1. Provenge
      • 9.2.1.4. Target Therapy
        • 9.2.1.4.1. Xofigo
      • 9.2.1.5. Others
    • 9.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Prostate Cancer Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment
        • 9.3.1.2.2. By End User
    • 9.3.2. Argentina Prostate Cancer Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment
        • 9.3.2.2.2. By End User
    • 9.3.3. Colombia Prostate Cancer Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment
        • 9.3.3.2.2. By End User

10. Middle East and Africa Prostate Cancer Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
      • 10.2.1.1. Hormonal Therapy
        • 10.2.1.1.1. Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
        • 10.2.1.1.2. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
        • 10.2.1.1.3. Anti-Androgen
      • 10.2.1.2. Chemotherapy
        • 10.2.1.2.1. Taxotere
        • 10.2.1.2.2. Jevtana
      • 10.2.1.3. Immunotherapy
        • 10.2.1.3.1. Provenge
      • 10.2.1.4. Target Therapy
        • 10.2.1.4.1. Xofigo
      • 10.2.1.5. Others
    • 10.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. UAE Prostate Cancer Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment
        • 10.3.1.2.2. By End User
    • 10.3.2. Saudi Arabia Prostate Cancer Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment
        • 10.3.2.2.2. By End User
    • 10.3.3. Saudi Africa Prostate Cancer Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment
        • 10.3.3.2.2. By End User
    • 10.3.4. Turkey Prostate Cancer Therapeutics Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Treatment
        • 10.3.4.2.2. By End User
    • 10.3.5. Egypt Prostate Cancer Therapeutics Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Treatment
        • 10.3.5.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
    • 11.1.1. Increasing Prevalence of Prostate Cancer.
    • 11.1.2. Adoption of Novel Screening and Diagnostic Technologies
    • 11.1.3. Surge in Research and Development
  • 11.2. Challenges
    • 11.2.1. High Cost of Cancer Treatment
    • 11.2.2. Side Effects of Hormonal Treatment

12. Market Trends & Developments

  • 12.1. Product Launches
  • 12.2. Mergers & Acquisitions
  • 12.3. Technological Advancements

13. Clinical Trial Analysis

14. Global Prostate Cancer Therapeutics Market: SWOT Analysis

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Product Offerings
  • 15.3. Recent Developments
  • 15.4. Financials (In Case of Listed Companies)
  • 15.5. Key Personnel
  • 15.6. SWOT Analysis
    • 15.6.1. Johnson & Johnson Services, Inc.
    • 15.6.2. Astellas Pharma Inc.
    • 15.6.3. Eli Lilly and Company
    • 15.6.4. Sanofi S.A.
    • 15.6.5. Ipsen Pharma
    • 15.6.6. Bayer AG
    • 15.6.7. AstraZeneca Plc
    • 15.6.8. Valeant Pharmaceuticals International, Inc.
    • 15.6.9. Merck & Co., Inc.
    • 15.6.10. Pfizer Inc.

16. Strategic Recommendations